In This Article:
Bayer’s BAYRY wholly owned and independently operated subsidiary, Vividion Therapeutics, Inc, announced that the first patient has been dosed in a phase I study evaluating VVD-159642.
VVD-159642 is an investigational oral inhibitor designed to target RAS-driven cancers.
The phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either Lumakras (sotorasib) or trametinib in patients with advanced solid tumors.
Shares of BAYRY have surged 20.3% year to date compared with the industry’s growth of 1.2%.
Image Source: Zacks Investment Research
More on BAYRY’s VVD-159642
VVD-159642 is Vividion’s fourth clinical-stage program stemming from its chemoproteomics discovery platform.
It is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway implicated in solid tumor development and progression.
Data from preclinical studies on VVD-159642 suggest that the candidate can be evaluated in a broad patient population and might demonstrate increased efficacy in combination with other RAS/MAPK pathway inhibitors.
Bayer acquired clinical stage biopharmaceutical company Vividion Therapeutics in 2021 to expand in the field of precision small-molecule therapeutics primarily in oncology and immunology. The chemoproteomics platform technology of Vividion has enabled Bayer to discover a large number of traditionally unaddressable oncological targets with the aid of precision cancer therapeutics.
Vividion is currently evaluating an oral KEAP1 activator in solid tumors and an oral STAT3 inhibitor in solid and hematologic malignancies in phase I studies.
In December 2024, Vividion acquired Tavros Therapeutics, Inc., a company based in the United States. Tavros’ proprietary methods for genomic screening can identify new target opportunities and support discovery and translational efforts toward known targets.
BAYRY Looks to Strengthen Pharma Pipeline
2024 was a challenging year for the company, largely due to strong headwinds in the Crop Science business. The uncertainty caused by ongoing Roundup litigation is also a major hangover on the stock. The guidance for 2025 is pretty ordinary, as Bayer expects business to be challenging.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote
In this scenario, the company aims to strengthen its pharmaceutical pipeline.
Bayer has expanded its pipeline in new modalities of cell therapy, through the acquisition of BlueRock, and gene therapy, through the acquisition of AskBio.